Deutsche Bank lowered the firm’s price target on Sanofi (SNY) to EUR 100 from EUR 105 and keeps a Buy rating on the shares.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi’s Rezurock recommended for EU approval by the CHMP
- Sanofi Posts Strong 2025 Sales and EPS Growth, Sets High-Single-Digit Outlook for 2026
- Sanofi reports Q4 business EPS EUR 1.53, up 16.8% reported
- Sanofi expects FY26 sales to grow by high single-digit percentage at CER
- Sanofi: De‑Risked Earnings and Robust Medium‑Term Growth Overlooked by Discounted Valuation